陀尼达安 | 50454-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 陀尼达安
• 中文别名: 托尼达明
• 英文名称: Tolnidamine
• 英文别名: 1-(4-chloro-2-methyl-benzyl)-1H-indazole-3-carboxylic acid；1-[(4-chloro-2-methylphenyl)methyl]indazole-3-carboxylic acid
• CAS: 50454-68-7
• 化学式: C₁₆H₁₃ClN₂O₂
• 分子量: 300.744
• InChiKey: IWKDFIXLGQOEKD-UHFFFAOYSA-N

物化性质

• 熔点：
  220°C (rough estimate)
• 密度：
  1.2682 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	ethyl 1-(4-chloro-2-methylbenzyl)-1H-indazole-3-carboxylate	1186610-38-7	C18H17ClN2O2	328.798
  ——	1-(4-chloro-2-methylbenzyl)-1H-indazole-3-carboxaldehyde	1186610-41-2	C16H13ClN2O	284.745
  ——	ethyl lonidamine	50264-84-1	C17H14Cl2N2O2	349.216
  ——	2-[1-(4-chloro-2-methylbenzyl)-1H-indazol-3-yl]propan-2-ol	1186610-37-6	C18H19ClN2O	314.815

反应信息

• 作为反应物：
  描述：

  陀尼达安 在 氯化亚砜 作用下， 以 甲苯 为溶剂， 反应 5.5h， 生成
  参考文献：
  名称：

  [EN] 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40
  [FR] NOUVEAUX DÉRIVÉS DE 1-BENZYL-3-HYDROXYMÉTHYLINDAZOLE ET LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES BASÉES SUR L'EXPRESSION DE MCP-1, CX3CR1 ET P40

  摘要：

  公开号：

  WO2009109616A8

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Lonidamine analogs
  申请人：Matteucci Mark

  公开号：US20070015771A1

  公开（公告）日：2007-01-18

  Lonidamine analogs are useful in the treatment and prevention of cancer, benign prostatic hyperplasia, macular degeneration and prostatic intraepithelial neoplasia, or for use as an antispermatigenic agent.

  Lonidamine类似物在治疗和预防癌症、良性前列腺增生、黄斑变性和前列腺上皮内瘤变方面非常有用，或者用作抗精子生成剂。
• 1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1 AND P40
  申请人：Guglielmotti Angelo

  公开号：US20110082141A1

  公开（公告）日：2011-04-07

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及根据权利要求中所述的式(I)所描述的新型1-苄基-3-羟甲基吲唑衍生物，以及包含它们的制药组合物和与药学上可接受的载体一起使用。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备活性用于治疗基于MCP-1、CX3CR1和p40表达的疾病的制药组合物，并将其用于治疗或预防基于MCP-1、CX3CR1和p40表达的疾病的方法。
• 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40
  申请人：Guglielmotti Angelo

  公开号：US08461194B2

  公开（公告）日：2013-06-11

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to Formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及一种新型1-苄基-3-羟甲基吲唑衍生物，其化学式（I）如权利要求中所述，以及包含它们的制药组合物和药用载体。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备对基于MCP-1、CX3CR1和p40表达的疾病具有活性的制药组合物，以及它们在治疗或预防基于MCP-1、CX3CR1和p40表达的疾病的方法中的使用。
• 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
  申请人：AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.p.A.

  公开号：US09255073B2

  公开（公告）日：2016-02-09

  The present invention relates to novel 1-benzyl-3-hydroxymethylindazole derivatives according to formula (I) described in the claims, and to a pharmaceutical composition comprising them, together with a pharmaceutically acceptable vehicle. In addition, the present invention relates to the use of 1-benzyl-3-hydroxymethylindazole derivatives for the preparation of a pharmaceutical composition that is active in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40, and to their use in a method for treating or preventing diseases based on the expression of MCP-1, CX3CR1 and p40.

  本发明涉及一种新型的1-苄基-3-羟甲基吲唑衍生物，其化学式（I）如权利要求书所述，并且涉及包含它们的制药组合物，以及与药学上可接受的载体一起使用的制药组合物。此外，本发明还涉及使用1-苄基-3-羟甲基吲唑衍生物制备对基于 MCP-1、CX3CR1 和 p40 表达的疾病具有活性的制药组合物，并将它们用于治疗或预防基于 MCP-1、CX3CR1 和 p40 表达的疾病的方法。